跳至主要内容
临床试验/NCT01544907
NCT01544907已完成不适用

Prospective Randomized Trial Comparing Drug Eluting Balloon Angioplasty Versus Conventional Percutaneous Transluminal Angioplasty Balloon for the Treatment of Hemodialysis Arterio-Venous Fistula or Arterio-Venous Graft Stenoses

Singapore General Hospital2 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2012年1月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
125
试验地点
2
主要终点
Late luminal loss

研究概览

简要总结

A prospective randomized trial comparing the efficacy of drug eluting balloon angioplasty versus conventional percutaneous transluminal angioplasty balloon for the treatment of hemodialysis arterio-venous fistula or arterio-venous graft stenoses in reducing late luminal loss and restenosis rates, while prolonging primary and secondary patencies.

详细描述

Introduction:

Neointimal hyperplasia is the main cause of hemodialysis access [arterio-venous fistula (AVF) or graft (AVG)] dysfunction and thrombosis. Although endovascular techniques like percutaneous transluminal angioplasty (PTA), catheter directed thrombolysis, mechanical thrombectomy or bare metal stenting, may salvage the access, long term patency remains dismal due to recurrent stenosis from neointimal hyperplasia.

Drug Eluting Balloon (DEB) is effective in inhibiting neointimal hyperplasia for treatment of coronary in-stent restenosis since 2006 and more recently in femoropopliteal arteries, reducing restenosis rates and prolonging patency.

Specific Aim:

To determine the efficacy of DEB in reducing restenosis rates and prolonging the patency of AVFs/AVGs compared to PTA.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Upper limb or groin AVF/AVG
  • The AVF/AVG is > 3 months old.
  • Native vessel measures between 4 to 7 mm diameter (corresponding to the sizes of available DEBs).
  • The fistula or graft must not be thrombosed.
  • Able to cross with guide wire
  • Platelet count >50,000/l (platelet infusion if <100,000/l)
  • PT/PTT not more than 3 seconds above normal (FFP infusion for abnormal PT/PTT)

排除标准

  • Uncorrectable coagulopathy (despite transfusion) or hypercoagulable state.
  • Evidence of systemic infection or a local infection associated with the fistula or graft.
  • The patient is < 21 years of age.
  • The patient is pregnant.
  • Patient is enrolled in another investigational study
  • Patient has comorbid conditions that may limit their ability to comply with the follow-up requirement.
  • Life expectancy < 6 months

研究组 & 干预措施

Conventional PTA only

Active Comparator

Treatment Arm 1- Conventional PTA only

The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.

An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.

At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation.

干预措施: Conventional PTA (Device)

Drug Eluting Balloon (DEB)

Experimental

Treatment arm 2 - Conventional Balloon with DEB

A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel.

干预措施: Drug Eluting Balloon (DEB) (Device)

结局指标

主要结局

Late luminal loss

时间窗: 6 months

Late luminal loss is defined as the difference between the minimum lumen diameters after angioplasty and at the end of the 6-month follow-up angiogram.

次要结局

  • Secondary patency(6 months)
  • Clinical success(Immediate post procedure)
  • Primary patency(6 months)
  • Primary assisted patency(6 months)
  • Restenosis rate(6 months)
  • Anatomic success(Immediate post procedure)
  • Procedural success(Immediate post procedure)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验